linkedin
BROUGHT TO YOU BY
Exclusive Access, Inclusive Growth

WELCOME TO ET PRIME

BROUGTH TO YOU BY
Exclusive Access, Inclusive Growth
ET Prime
Alternative therapy

Hip hip hurray: homegrown cell therapy Ossgrow is quietly changing the lives of hip-replacement patients

Patients suffering from decomposition of the hip joint have had little recourse save hip implants when the disease reaches an advanced stage. Then there’s the risk of painful revision surgeries. A Mumbai-based company’s innovation holds out new hope.
font size
FONT SIZE
save
SAVE
saved
SAVED
Gift this article
GIFT ARTICLE
By
18 Oct 2018 7 Mins Read 0 comment
Yash Sanghvi, Satyen Sanghvi, and Prathap C Reddy of Apollo Hospital; Regrow via Facebook
Yash Sanghvi, Satyen Sanghvi, and Prathap C Reddy of Apollo Hospital; Regrow via Facebook
Culangattil Mery George was losing hope. The 61-year-old nurse from Mumbai was diagnosed with avascular necrosis (AVN) of the hip, a progressive disease where blood supply to the hip joint is obstructed, slowly killing the bone. It has four stages, and symptoms such as pain and defective gait are visible from the onset. Historically, patients with George’s condition
drug, globally,” says the junior Sanghvi. “The potential is huge. Right now, we don’t have competition. We have already been given drug status in India, which gives us a lead time of at least three years. We are getting ready to file for approvals in the US and the EU by early next year.” ( Graphics by Abdul Shafiq)
Culangattil Mery George was losing hope. The 61-year-old nurse from Mumbai was diagnosed with avascular necrosis (AVN) of the hip, a progressive disease where blood supply to the hip joint is obstructed, slowly killing the bone. It has four stages, and symptoms such as pain and defective gait are visible from the onset. Historically, patients with George’s condition drug, globally,” says the junior Sanghvi. “The potential is huge. Right now, we don’t have competition. We have already been given drug status in India, which gives us a lead time of at least three years. We are getting ready to file for approvals in the US and the EU by early next year.” ( Graphics by Abdul Shafiq)

The latest from ET Prime is now on Telegram. To subscribe to our Telegram newsletter click here.

Gift this story

YOU CAN GIFT 0 MORE STORIES THIS MONTH

Maximum 10 Email IDs allowed

300 characters remaining

Gift Sent Successfully

Limit Reached
Limit Reached

You’ve gifted all the 0 articles from your monthly gift bucket!

Please come back next month.

0 more articles will be waiting for you in your gift bucket.

Current Edition

An auto-industry recovery appears far away. Vehicle-carrier companies are drastically scaling down.
Logistics

An auto-industry recovery appears far away. Vehicle-carrier companies are drastically scaling down.

Automobile-transportation companies are awash in debt, with mounting losses. A key pillar of the auto-sector supply chain, many of them face an uncertain future and are selling off their prime assets – trailers and trucks for carrying cars and two-wheelers. These carriers have a chilling assessment of the ground realities. An auto-sector recovery is far, far away, they say.

headset AUDIO SUMMARY . 01:28
Maruti, Hyundai, et al. have a foggy view on demand. The way out: a tweak in the forecasting method
Automobile

Maruti, Hyundai, et al. have a foggy view on demand. The way out: a tweak in the forecasting method

Automakers will have to be more innovative in terms of demand forecasts. Use of a scenario-based forecasting methodology for the next few quarters could help. Time-series forecasts, based on historical data, won’t work in these uncertain times. Every associated element of the business — from production to sales, and logistics to component supply — needs to adopt a flexible approach.

headset AUDIO SUMMARY . 01:19
[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]